A review on mucoadhesive polymer used in nasal drug delivery system

Journal of Advanced Pharmaceutical Technology and Research

Volumn 2, Issue 4, 2011, Pages 215-222

  Chaturvedi, Mayank ^a   Kumar, Manish ^a   Pathak, Kamla ^a  

^a Rajiv Academy for Pharmacy ^*  (India)

Author keywords

In vivo; mucoadhesive polymers; nasal drug delivery system

Indexed keywords

AMASTATIN; APOMORPHINE; CELLULOSE DERIVATIVE; CHITOSAN; CIPROFLOXACIN; DOPAMINE; GENTAMICIN; GLYCERYL TRINITRATE; INFLUENZA VACCINE; INSULIN; KETOROLAC; KETOROLAC TROMETAMOL; LEUPRORELIN; LEVONORGESTREL; METOCLOPRAMIDE; NANOMATERIAL; NIFEDIPINE; POLYACRYLIC ACID; POLYMER; PUROMYCIN; STARCH; TETRAMETHYLPYRAZINE; THIOMERSAL;

AEROSOL; ANATOMICAL VARIATION; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SOLUTION; DRY POWDER; GELATINIZATION; HUMAN; HYDROGEL; IN VIVO STUDY; LIPOSOMAL DELIVERY; MUCOADHESION; NANOPHARMACEUTICS; NONHUMAN; NOSE MUCOSA; PARTICULATE MATTER; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; SOLID STATE; SUSPENSION;

EID: 84855216636     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.90876     Document Type: Review

References (58)

1. Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Madhusudan Rao YM. Polymers for mucoadhesive drug delivery system: A current status. Drug Dev Ind Pharm 2008;34:1246-66.
2. Harris AS. Review: Clinical opportunities provided by the nasal administration of peptides. J Drug Targeting 1993;1:101-16.
3. Chien YW, Chang SF. In: Nasal Systemic Drug Delivery. New York: Dekker; 1989. p. 1-26.
4. Limzerwala RB, Paradkar AR, Pawar AP, Mahadik KR. Nasal drug absorption; Review article. Indian Drug 1995;33:243-50.
5. Lisbeth I. Nasal drug delivery- possibilities problems and solutions. J Control Release 2003;87:187-98.
6. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217:183-91. (Pubitemid 32268644)
7. Ugwoke MI, Kaufmann G, Verbeke N, Kinget R. Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Int J Pharm 2000;202:125-31. (Pubitemid 30466238)
8. Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology. 17th ed, Harper Collins College Publishers; 2001.
9. Nielsan HW, Bichgaard E, Twile B. Intra nasal administration of different liquid formulations of bumentanide to rabbit. Int J Pharm 2000;204:35-41.
10. Joshi M, Misra A. Dry powder inhalation of liposomal Ketotifen fumarate; formulation and characterization. Int J Pharm 2001;223:15-27. (Pubitemid 32640874)
11. Kublik H, Vidgren MT. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998;29:157-77. (Pubitemid 28044092)
12. Castellanos J, Zia H, Rhodes CT. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm 1993;19:143-94.
13. Lee WA, Narog BA, Patapoff TW, Wang YJ. Intranasal bioavailability of insulin powder formulations: Effect of permeation enhancer-toprotein ratio. J Pharm Sci 1991;80:725-9.
14. Garmise RJ, Staats HF, Hickey AJ. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS Pharm Sci Tech 2007;8:E81.
15. Wadell C. Nasal Drug Delivery - In vitro studies on factors influencing permeability and implication on absorption. Drug Metabolism. Revi. 1999;7:197-206
16. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70:735-40.
17. Miyamoto M, Natsume H, Iwata S, Ohtake K, Yamaguchi M, Kobayashi D, et al. Improved nasal absorption of drugs using polyl- arginine: Effects of concentration and molecular weight of poly l-arginine on the nasal absorption of fluorescein isothiocyanatedextran in rats. Eur J Pharm Biopharm 2001;52:21-30. (Pubitemid 32594786)
18. Calvo P, Remunan-Lopez C, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999;16:1576-81.
19. Jain AK, Khar RK, Ahmed FJ, Diwan PV. Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm 2008;69:426-35.
20. Donovan MD, Huang Y. Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Deliv Rev 1998;29:147-55. (Pubitemid 28044091)
21. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Contr Rel 2006;111:107-16. (Pubitemid 43290000)
22. Tengamnuay P, Sahamethapat A, Sailasuta A, Mitra AK. Chitosans as nasal absorption enhancers of peptides: Comparison between free amine chitosans and soluble salts. Int J Pharm 2000;197:53-67. (Pubitemid 30125777)
23. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009;61:140-57.
24. Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev 1998;29:185-94. (Pubitemid 28044094)
25. Mishra PR, Namdeo A, Jain S, Jain NK. Hydrogel as drugdelivery system. Indian Drugs 1998;33:181-6.
26. Kawasaki N, Ohkura R, Miyazaki S. Thermally reversible xyloglucan gets as vehicles for oral drug delivery. Int J Pharm 1999;181:227-34. (Pubitemid 29229809)
27. Shahiwala A, Misra A. Nasal delivery of levonorgestrel for contraception: An experimental study in rats. Fertil Steril 2004;81:893-8. (Pubitemid 38333077)
28. Suzuki Y, Makino Y. Mucosal drug delivery using cellulose derivatives as a functional polymer. J Control Release 1999;62:101-7. (Pubitemid 29486488)
29. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm 1997;23:489-515. (Pubitemid 27241128)
30. Luessen HL, De-Leeuw BJ, Langemeyer M, De-Boer AG, Verhoef JC, Unginger HE. Mucoadhesive polymers in peroral peptide drug delivery. IV. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 1996;13:1668-72. (Pubitemid 26426890)
31. Jabbal-Gill I, Fisher AN, Farraj N, Pitt CG, Davis SS, Illum L. Intranasal absorption of granulocyte-colony stimulating factor (G-CSF) from powder formulations, in sheep. Eur J Pharm Sci 1998;6:1-10. (Pubitemid 28035219)
32. Zaki NM, Awada GA, Mortadaa ND, Abd ElHadyb SS. Enhanced bioavailability of metoclopramide HCl by intranasal administration of mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci 2007;32:296-307. (Pubitemid 350064481)
33. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70:735-40.
34. Ugwoke MI, Sam E, Van Den Mooter G, Verbeke N, Kinget R. Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur J Pharm Sci 1999;9:213-9. (Pubitemid 30012078)
35. Quadir M, Zia H, Needham TE. Toxicological implications of nasal formulations. Drug Del 1999;6:227-42. (Pubitemid 30003326)
36. Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H. Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 2006;64:246-54. (Pubitemid 44308522)
37. Paulsson M. Controlled Release Gel Formulation for Mucosal Drug Delivery. ACTA Universitatis Upsaliensin Uppasla 2001;7:9-21
38. Ikeda K, Murata K, Kobayashi M, Noda K. Enhancement of bioavailability of dopamine via nasal route in beagle dogs. Chem Pharm Bull 1992;40:2155-8.
39. Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. Chitosan/ cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 2009;71:257-63.
40. Vidgren P, Vidgren M, Arppe J, Hakuli T, Laine E, Paronen P. In vitro evaluation of spray-dried mucoadhesive microspheres for nasal administration. Drug Dev Ind Pharm 1992;18:581-97.
41. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 2005;57:1556-68. (Pubitemid 41443469)
42. Callens C, Remon JP. Evaluation of starchmaltodextrin-Carbopol 974P mixtures for the nasal delivery of insulin in rabbits. J Contr Rel 2000;66:215-20. (Pubitemid 30160858)
43. Callens C, Pringels E, Remon JP. Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. Int J Pharm 2003;250:415-22. (Pubitemid 36084364)
44. Quadir M, Zia H, Needham TE. Development and evaluation of nasal formulations of ketorolac. Drug Deliv 2000;7:223-9. (Pubitemid 32057554)
45. Illum L, Jorgensen H, Bisgaard H, Krogsgaard O, Rossing N. Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm 1987;39:189-99. (Pubitemid 17147761)
46. Illum L. Nasal drug delivery: New developments and strategies. Drug Discov Today 2002;7:1184-9. (Pubitemid 35430155)
47. Cui F, Qian F, Yin C. Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int J Pharm 2006;316:154-61. (Pubitemid 43765702)
48. Sriamornsak P, Wattanakorn N, Nunthanid J, Puttipipatkhachorn S. Mucoadhesion of pectin as evidence by wettability and chain interpenetration. Carbohydr. Polym 2008;74:458-67.
49. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco- 2). Pharm Res 1994;11:1358-61. (Pubitemid 24287420)
50. Chung T, Liu D, Yang J. Effects of interpenetration of thermosensitive gels by crosslinking of chitosan on nasal delivery of insulin: In vitro characterization and in vivo study. Carbohydrate Polymers 2010;82:316-22.
51. Issa MM, Koping-Hoggard M, Artursson P. Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov Today 2005;2:1-6. (Pubitemid 40946301)
52. Kotze AF, Luesen HL, De Boer AG, Verhoef JC, Junginger HE. Chitosan for enhanced intestinal permeability: Prospects for derivatives soluble in neutral and basic environments. Eur J Pharm Sci 1999;7:145-51. (Pubitemid 29056237)
53. Thanou M, Verhoef JC, Verheijden JH, Junginger HE. Intestinal absorption of octeriotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci 2000;89:951-7.
54. Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release 2009;134:158-68.
55. Mei D, Mao S, Sun W, Wang Y, Kissel T. Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur J Pharm Biopharm 2008;70:874-81.
56. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001;52:145-50. (Pubitemid 33079170)
57. VanderLubben IM, Kersten G, Fretz MM, Beuvery C, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria oral and nasal efficacy studies in mice. 2003;21:1400-8.
58. Bacon A, Makin J, Sizer P J, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000;68:5764-70.